Friday, November 17, 2017
Innovus Pharmaceuticals, Inc., an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases, today announced that it has received a Notice of Allowance of the issuance of a patent from the Mexican Patent Office entitled “Sensitization Composition and Method of Use” for the Company’s Sensum+® product, for reduced penile sensitivity. The Mexican patent is scheduled to expire in 2033. This is the fourth major international patent notification that Innovus Pharma has received on its Sensum+® product in 2017, the first being the Company’s receipt of a Notice of Intention to Grant a patent for all 28 countries of the European Union announced on March 27, 2017, the issuance of a patent in Morocco on April 12, 2017 and in China on October 11, 2017.
Innovus Pharma has also previously filed patent applications for its Sensum+® product in Australia, Brazil, Israel, Japan, New Zealand and South Korea.
“I am very excited about the continued expansion of our proprietary patent coverage for Sensum+, one of our core products, to now include 31 countries in the world,” said Dr. Bassam Damaj, the President and Chief Executive Officer of Innovus Pharma. “To date, we have 16 issued patents and seven patent applications covering our core products and we look forward to increasing that number in 2017 and 2018 and to enhancing the proprietary nature of such products in the marketplace.”